ABBVAbbVie Inc.
Pharmaceutical Preparations
- Revenue
- $61.2B
- 8.6% YoY
- Operating margin
- 24.6%
- 52% YoY
- EBITDA
- $15.8B
- 60% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 3.5×
- $55.9B net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear450% of net incomeCash flow under 80% of net income
- Dilutive SBCClear2% of revenueOver 10% of revenue
- Payouts exceed cash flowClear66% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear26% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $56.2B | $58.1B | $54.3B | $56.3B | $61.2B | 8.6% |
| Operating income | $17.9B | $18.1B | $12.8B | $9.1B | $15.1B | 65% |
| Net income | $11.5B | $11.8B | $4.9B | $4.3B | $4.2B | 1.2% |
| Operating cash flow | $22.8B | $24.9B | $22.8B | $18.8B | $19.0B | 1.2% |
| Capex | $787M | $695M | $777M | $974M | $1.2B | 25% |
| Stock-based comp | $692M | $671M | $747M | $911M | $955M | 4.8% |
| Buybacks | $934M | $1.5B | $2.0B | $1.7B | $980M | 43% |
| Dividends | $9.3B | $10.0B | $10.5B | $11.0B | $11.7B | 5.7% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.